Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial

Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial

Abstract Background Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in th...

Full description

Bibliographic Details
Main Authors: Sheraz Yaqub, Bjørn Atle Bjørnbeth, Jon-Helge Angelsen, Claus Wilki Fristrup, Jon Erik Grønbech, Oskar Hemmingsson, Bengt Isaksson, Ingebjørg Soterud Juel, Peter Nørgaard Larsen, Gert Lindell, Frank Viborg Mortensen, Kim Erlend Mortensen, Magnus Rizell, Per Sandström, Oddvar Mathias Sandvik, Ernesto Sparrelid, Helena Taflin, Kjetil Taskén, The ASAC study group
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Trials
Subjects:
Colorectal cancer
Liver metastases
Aspirin
Acetylsalicylic acid
Secondary prevention
Online Access:https://doi.org/10.1186/s13063-021-05587-w

Internet

https://doi.org/10.1186/s13063-021-05587-w

Similar Items